ALNEV.PA Neovacs (EURONEXT) €0.0012 after-hours, high volume: what investors watch 10 Mar 2026

ALNEV.PA stock moved higher in after-hours trading on 10 Mar 2026 to €0.0012, up 9.09% on a heavy 32,488,147 share print. This spike makes Neovacs S.A. (ALNEV.PA) one of the most active names on EURONEXT in Europe after the close. The move reflects very thin market capitalisation (€572.00) and extreme price sensitivity to any news or trading flows. We review liquidity, fundamentals, technicals, a proprietary Meyka grade, and a model forecast to put this level in context for traders and longer-term observers.

ALNEV.PA stock: trade snapshot and liquidity

Price and session: ALNEV.PA closed after-hours at €0.0012 with a session range of €0.0011–€0.0014.

Volume context: today’s 32,488,147 shares compare with a 30‑day average of 12,346,930, giving relative volume 1.41, which explains sharp intraday moves.

Market cap and float: market capitalisation is €572.00 with 476,625 shares outstanding, so even small orders move price materially.

ALNEV.PA stock: fundamentals and valuation

Profitability and earnings: last available EPS stands at -221.36, showing the company is loss-making and not P/E comparable.

Balance sheet snapshots: book value per share reads 103.50 but the quoted price disconnects price-to-book metrics, producing an effective PB of 0.00001 at the tiny market price.

Cash and ratios: cash per share is 2.50, current ratio 0.63, and research spend is high at 10.94% of revenues, reflecting ongoing R&D for Kinoid therapeutic vaccines.

ALNEV.PA stock: technicals and momentum

Momentum indicators: RSI is 14.39, signalling oversold conditions on standard indicators.

Trend and averages: 50‑day average is €0.00404 and 200‑day average is €0.64097, showing the price sits far below longer-term averages.

Historical range: year high is €130.00 and year low is €0.0011, emphasising extreme historical volatility and prior price adjustments that are not representative of current float dynamics.

ALNEV.PA stock: Meyka grade and analyst overview

Meyka AI rates ALNEV.PA with a score of 62.23 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Independent rating and caution: a separate company rating dated 2025‑02‑28 lists ALNEV.PA as C- (Strong Sell), reflecting weak profitability metrics and balance sheet stress; the divergence highlights model differences and data sensitivity for microcap biotech names.

Investor note: grades are informational and not investment advice; they reflect relative standing against healthcare peers and internal risk models.

ALNEV.PA stock: price forecast and scenario planning

Meyka AI’s forecast model projects a monthly price of €0.04, compared with the current €0.0012.

Implied move: that monthly forecast implies an upside of approximately 3233.33% from today’s price, but this is model‑based and assumes successful clinical or corporate catalysts.

Scenario targets: a conservative short‑term scenario is €0.0015, a base case is €0.02, and a bullish catalyst case aligns with the model at €0.04; all targets carry high probability of revision.

ALNEV.PA stock: risks, catalysts and sector context

Key risks: clinical trial outcomes, dilution from capital raises, regulatory setbacks, and extreme liquidity sensitivity due to tiny market cap are primary downside drivers.

Catalysts: Phase IIb IFNa Kinoid results, partnerships or licensing deals, and positive preclinical updates for VEGF‑Kinoid could re‑rate the stock.

Sector view: the Healthcare/Biotechnology peer group trades on much higher multiples and stronger current ratios; investors should weigh ALNEV.PA’s microcap traits against the sector’s average fundamentals.

Final Thoughts

ALNEV.PA stock is an extremely illiquid, highly volatile biotech microcap that traded at €0.0012 after hours on 10 Mar 2026 with outsized volume that amplified price moves. Fundamentals show large losses (EPS -221.36) and a market cap of €572.00, while technicals read as deeply oversold (RSI 14.39). Meyka AI assigns a 62.23/100 grade (B, HOLD) reflecting mixed signals from sector comparisons, metrics, and model forecasts. Meyka AI’s forecast model projects €0.04 monthly, implying ~3233.33% upside from the current price, but that projection is model‑based and not a guarantee. Given the clinical‑stage profile, the most realistic approach for investors is position sizing for high risk: treat trades as tactical, monitor trial updates and filings, and expect rapid repricing on news. For deeper tracking use our Meyka stock page for ALNEV.PA and the linked market feeds to follow real‑time liquidity and regulatory announcements.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.